PhaseBio raises $34M series D

PhaseBio Pharmaceuticals Inc. (Malvern, Pa.) raised $34 million in a series D round from new investors Cormorant Asset Management, Rock Springs Capital and Mountain Group Partners. Existing investors New Enterprise Associates, Hatteras Venture Partners, AstraZeneca plc (NYSE:AZN; LSE:AZN), Johnson & Johnson Innovation - JJDC Inc., Syno Capital and Fletcher Spaght Ventures also participated. ...